The Medicines and Healthcare products Regulatory Agency (MHRA) has recommended that the obesity drug sibutramine (marketed as Reductil) should be suspended until further notice. This suspension was announced in January 2010 and follows a review by the European Medicines Agency. They have found that there is an increased risk of non-fatal heart attacks and strokes […]